Is lipoxins a4 a better alternative to anti-VEGF and anti- TNF-α antibody to prevent and treat age-related macular degeneration, diabetic macular edema and retinopathy?

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Das, Undurti N ^a,b  

^a GAYATRI VIDYA PARISHAD COLLEGE OF ENGINEERING   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CD59 ANTIGEN; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; GAMMA INTERFERON; I KAPPA B KINASE BETA; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; LEUKOTRIENE; LIPOPROTEIN; LIPOXIN; LIPOXIN A; LIPOXIN B; OMEGA 6 FATTY ACID; PROSTAGLANDIN; RANIBIZUMAB; RESOLVIN; THROMBOMODULIN; THROMBOXANE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VON WILLEBRAND FACTOR;

CELL HYPOXIA; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; EYE TOXICITY; HUMAN; LETTER; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PROLIFERATIVE RETINOPATHY; PROTEIN BLOOD LEVEL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA CYSTOID EDEMA; SUBRETINAL NEOVASCULARIZATION; TH1 TH2 BALANCE; UVEITIS; VITREOUS BODY DETACHMENT;

EID: 84855267236     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882187     Document Type: Letter

References (13)

1. Markomichelakis NN, Theodossiadis PG, Sfikakis PP: Regression of neo-vascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol, 2005; 139: 537-40
2. Funatsu H, Yamashita H, Noma H et al: Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol, 2002; 133: 70-77
3. Itoi K, Nakamura K, Oku H et al: Relationship between diabetic macular edema and peripheral Th1/Th2 balance. Ophthalmologica, 2008; 222: 249-53
4. Sfikakis PP, Grigoropoulos V, Emfietzoglou I et al: Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care, 2010; 33: 1523-28
5. Giganti M, Beer PM, Lemanski N et al: Adverse events after intravitreal infliximab (Remicade). Retina, 2010; 30: 71-80
6. Figurska M, Stankiewicz A: Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes. Med Sci Monit, 2011; 17(9): 485-90
7. Das UN: Molecular Basis of Health and Disease. Springer, New York, 2011
8. Serhan CN: Novel chemical mediators in the resolution of inflammation: resolvins and protectins. Anesthesiol Clin, 2006; 24: 341-64
9. Zhang YW, Yao XS, Murota S, Morita I: Inhibitory effects of eicosapentaenoic acid (EPA) on the hypoxia/reoxygenation-induced tyrosine kinase activation in cultured human umbilical vein endothelial cells. Prostaglandins Leukot Essent Fatty Acids, 2002; 67: 253-61
10. Yang SP, Morita I, Murota SI: Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. J Cell Physiol, 1998; 176: 342-49
11. Fierro IM, Kutok JL, Serhan CN: Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15Rlipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther, 2002; 300: 385-92
12. Connor KM, SanGiovanni JP, Lofqvist et al: Increased dietary intake of w-3 polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med, 2007; 7: 868-73
13. Das UN: Polyunsaturated fatty acids in pathological retinal angiogenesis. Current Nutr Food Sci, 2009; 5: 94-111